You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Identification of Mixed NOP/mu partial agonists as lead compounds for treatment ofmethamphetamine use disorder
SBC: PHOENIX PHARMALABS, INC. Topic: NIDAAbstract Currently, clinically used drug abuse medications exist for treatment of addiction to opiates, alcohol, and nicotine, but not psychostimulants, such as methamphetamine (METH). Compounds that co-activate both nociceptin opioid peptide (NOP) and mu receptors have potential for treatment of drug abuse. In particular, buprenorphine, a partial mu agonist/kappa antagonist, which also acts as a ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Closed-loop laryngeal pacing for voice restoration
SBC: RIPPLE LLC Topic: NIDCDProject Summary and Abstract The most common neurogenic voice disorder is unilateral vocal fold paralysis (UVFP), which can substantially reduce quality of life. Current available surgical treatments offer only temporary improvement in voice through placement of resorbable materials or involve permanent, invasive alteration of the larynx that incompletely restores voice and often requires revision ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a Diagnostic Test for Eosinophilic Chronic Rhinosinusitis
SBC: GLYCOMIRA, LLC Topic: NIAIDPROJECT SUMMARYThe goal of this proposal is to optimize and clinically validate a new diagnostic test for eosinophilic chronic rhinosinusitis (eCRS) at the point-of-care, improving the efficiency, value, and accessibility of personalized medicine. eCRS affects up to 5 million Americans and is characterized by varying degrees of sinonasal and peripheral eosinophilia, linked to treatment responsiven ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Optimizing Small Molecule Mechanomimetics to Treat Age-related Osteoporosis.
SBC: OAK RIDGE THERAPEUTIC DISCOVERY LLC Topic: NIAAbstract There is an unmet need to develop treatments for senile osteoporosis, a disorder characterized by an age-related reciprocal decrease in osteogenesis and increase in bone marrow fat. Senile osteoporosis resembles disuse osteopenia, suggesting its pathogenesis involves impaired bone mechanosensing. We discovered that the polycystin heterotrimeric complex (1PC1+3PC2) functions as a mechanose ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Developing a selective TRPC3 ion channel inhibitor for epilepsy treatment
SBC: SEAK Therapeutics, LLC Topic: 106Project SummaryEpilepsy is one of the most common brain disorders. Current drugs have limited efficacy. Identifying new targeted drugs that can be used as safer, more effective therapies is in urgent unmet need. Selective inhibition of the transient receptor potential canonical 3 (TRPC3) emerges as a novel strategy to impede epilepsy. However, the currently best selective TRPC3 inhibitor, Pyr3, ha ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel Method for Renewable JP10 Production
SBC: Technology Holding, LLC Topic: N23AT015Currently, all JP10 is produced from fossil sources. The objective of the proposed project is to develop a scalable synthetic approach to producing JP-10 that meets military specification, MIL-DTL-87107E from non-fossil sustainable energy resources. During phase I, we will define, develop, and perform initial laboratory assessment of the proposed synthetic process to validate the technical feasi ...
STTR Phase I 2023 Department of DefenseNavy -
Capture and Conversion of Environmental CO2 into Carbon Nanotube Additives for Superior Performance Low-Emissions Concrete Composites
SBC: SKYNANO LLC Topic: N23AT020In this STTR effort, SkyNano will collaborate with Prof. Hongyu Zhou's laboratory at the University of Tennessee Knoxville (UTK) to demonstrate the utilization of environmental carbon in composite applications specific to meeting the needs of the Department of the Navy. SkyNano will leverage our core technology which captures and converts environmental carbon dioxide into functional all-carbon ...
STTR Phase I 2023 Department of DefenseNavy -
Steerable, Directional Antennas to Increase Small Mobile Platform Communication Range
SBC: IMSAR LLC Topic: N22AT021Traditionally, small platforms that need to communicate with airborne platforms use omnidirectional antennas. This makes it simple to communicate with mobile airborne platforms but reduces the communication link range compared to directional antennas. However, directional antennas require pointing at the airborne platform, which requires a means of moving the antenna to follow the motion of the ai ...
STTR Phase I 2022 Department of DefenseNavy -
Cell permeant peptidomimetics to prevent delayed vasospasm and neurological deficits after subarachnoid hemorrhage
SBC: VasaMetrix Topic: 107PROJECT SUMMARYSubarachnoid hemorrhage (SAH) due to rupture of an intracranial aneurysm leads to delayed vasospasm resulting in neuroischemia (stroke). The overall morbidity (profound neurologic deficit in 10-20% of survivors) and mortality (50%) are high, and the disease affects a relatively young adult population. Therapeutic options to prevent delayed vasospasm and neuroischemia after SAH are c ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
A web-based platform to support team-based genome diagnostics
SBC: FRAMESHIFT LABS INC Topic: 172Summary/Abstract Genomic sequencing is rapidly becoming a standard tool in diagnosing complex diagnostic cases, especially in critically ill newborns, and patients suffering from rare diseases. Current programs focused on addressing these cases utilise a team-based approach to identify, interpret and evaluate a patient’s genetic variants. These diverse teams include bioinformaticians, medical ge ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health